| 前收市價 | 72.00 |
| 開市 | 82.63 |
| 買盤 | 76.00 |
| 賣出價 | 85.00 |
| 拍板 | 1,200.00 |
| 到期日 | 2025-12-19 |
| 今日波幅 | 72.00 - 83.56 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 101 |
Insider MonkeyJim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling’
We recently compiled a list of the Cramer’s Morning Thoughts: 20 Stocks to Watch. In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands against the other stocks to watch according to Jim Cramer. In a recent episode of Mad Money, Jim Cramer explains that if you’re investing with […]
BloombergRegeneron Shares Head for Worst Month Since 2019 on Legal Ruling
(Bloomberg) -- Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2019 after a legal setback that opens the door to an early launch of a competing therapy to the drugmaker’s blockbuster eye treatment, Eylea.Most Read from BloombergClimate Migrants Stand to Overwhelm World’s MegacitiesVanderbilt Leases Struggling NYC Seminary for Campus ExpansionNew Rowhouses in London That Offer a Bridge to the 19th CenturyNJ Transit, Amtrak Trains Delayed After Derailment
Investor's Business DailyRegeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
Regeneron stock rose Friday after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.
